Evidence map›Paper›PMID 28562350›Full record

ArticleOncotarget2017

U94 of human herpesvirus 6 down-modulates Src, promotes a partial mesenchymal-to-epithelial transition and inhibits tumor cell growth, invasion and metastasis.

Francesca Caccuri, Roberto Ronca, Andrea S Laimbacher, Angiola Berenzi, Nathalie Steimberg, Federica Campilongo, Pietro Mazzuca, Arianna Giacomini, Giovanna Mazzoleni, Anna Benetti and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Francesca CaccuriDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Roberto RoncaDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Andrea S LaimbacherInstitute of Virology, University of Zurich, Zurich, Switzerland.
Angiola BerenziDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Nathalie SteimbergDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Federica CampilongoDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Pietro MazzucaDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Arianna GiacominiDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Giovanna MazzoleniDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Anna BenettiDepartment of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.
Elisabetta CaselliDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Marco PrestaDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
Dario Di LucaDepartment of Medical Sciences, University of Ferrara, Ferrara, Italy.
Cornel FraefelInstitute of Virology, University of Zurich, Zurich, Switzerland.
Arnaldo CarusoDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
University of Brescia · ITUniversity of Ferrara · ITUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

U94, the latency gene of human herpesvirus 6, was found to inhibit migration, invasion and proliferation of vascular endothelial cells (ECs). Because of its potent anti-migratory activity on ECs, we tested the capability of U94 to interfere with the individual steps of the metastatic cascade. We examined the U94 biological activity on the human breast cancer cell line MDA-MB 231, as a model of highly aggressive cancer cell. Here we show that the expression of U94 delivered by an HSV-1-based amplicon promoted down-modulation of Src and downstream molecules linked to cell motility and proliferation. Indeed, U94 expression strongly inhibited cell migration, invasiveness and clonogenicity. We investigated the effects of U94 in a three-dimensional rotary cell-culture system and observed the ability of U94 to modify tumor cell morphology by inducing a partial mesenchymal-to-epithelial transition. In fact, despite U94 did not induce any expression of the epithelial marker E-cadherin, it down-modulated different mesenchymal markers as β-catenin, Vimentin, TWIST, Snail1, and MMP2. In vivo data on the tumorigenicity of MDA-MB 231 displayed the capability of U94 to control tumor growth, invasiveness and metastasis, as well as tumor-driven angiogenesis. The antitumor U94 activity was also confirmed on the human cervical cancer cell line HeLa. The ability of U94 to inhibit cell growth, invasion and metastasis opens the way to a promising field of research aimed to develop new therapeutic approaches for treating tumor and cancer metastasis.

Indexed as

Gene Expression Regulation, NeoplasticGenes, srcAnimalsCell Cycle CheckpointsCell Line, TumorCell MovementCell ProliferationCell Transformation, NeoplasticDisease Models, AnimalEpithelial-Mesenchymal TransitionFemaleGene ExpressionHerpesvirus 6, HumanHeterograftsHumansMiceViral Proteinscancer development and metastasisHHV-6 U94HSV-1 amplicon vectormesenchymal-to-epithelial transitionSrc signaling pathway

Identifiers

PMID28562350
PMCPMC5546500
OpenAlexW2613558542

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.